The AhR has emerged as a potential drug target for multiple diseases including cancer; however, there are still some conflicting reports regarding the pro-oncogenic or tumor suppressor-like activity of the receptor and its ligands and this is particularly true for breast cancer [15,16]. The gene discussed is AHR; the disease is neoplasm.